A carregar...
A budget impact analysis of the introduction of erythropoiesis stimulating agent subsequent entry biologics for the treatment of anemia of chronic kidney disease in Canada
BACKGROUND: In Europe, epoetin subsequent entry biologics (SEBs) have been in use since 2007. Canadian patents of erythropoietin stimulating agents are expiring in 2014, therefore it is predicted that epoetin SEBs will penetrate the Canadian market in the near future. OBJECTIVE: To estimate the econ...
Na minha lista:
| Publicado no: | Can J Kidney Health Dis |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BioMed Central
2014
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4349794/ https://ncbi.nlm.nih.gov/pubmed/25780617 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40697-014-0028-3 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|